Travere Therapeutics Inc (TVTX) - Total Liabilities
Based on the latest financial reports, Travere Therapeutics Inc (TVTX) has total liabilities worth $490.36 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore TVTX cash flow conversion to assess how effectively this company generates cash.
Travere Therapeutics Inc - Total Liabilities Trend (2010–2025)
This chart illustrates how Travere Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Check TVTX cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Travere Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Travere Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Browave
TWO:3163
|
Taiwan | NT$887.78 Million |
|
Kyndryl Holdings Inc
NYSE:KD
|
USA | $9.97 Billion |
|
Xiamen Leading Optics Co Ltd
SHG:605118
|
China | CN¥282.02 Million |
|
Schneider National Inc
NYSE:SNDR
|
USA | $1.96 Billion |
|
Lisi S.A
PA:FII
|
France | €1.30 Billion |
|
Arcplus Group PLC
SHG:600629
|
China | CN¥9.74 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $243.49 Million |
|
FB Financial Corp
NYSE:FBK
|
USA | $14.26 Billion |
Liability Composition Analysis (2010–2025)
This chart breaks down Travere Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Travere Therapeutics Inc (TVTX) total market value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 4.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.81 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Travere Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Travere Therapeutics Inc (2010–2025)
The table below shows the annual total liabilities of Travere Therapeutics Inc from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $490.36 Million | -8.35% |
| 2024-12-31 | $535.05 Million | -9.02% |
| 2023-12-31 | $588.10 Million | -6.61% |
| 2022-12-31 | $629.73 Million | +32.71% |
| 2021-12-31 | $474.52 Million | +19.76% |
| 2020-12-31 | $396.23 Million | +3.29% |
| 2019-12-31 | $383.60 Million | -1.87% |
| 2018-12-31 | $390.91 Million | +72.05% |
| 2017-12-31 | $227.21 Million | +4.46% |
| 2016-12-31 | $217.51 Million | +2.39% |
| 2015-12-31 | $212.43 Million | +22.99% |
| 2014-12-31 | $172.72 Million | +345.04% |
| 2013-12-31 | $38.81 Million | +569.26% |
| 2012-12-31 | $5.80 Million | +8556.76% |
| 2011-12-31 | $66.99K | +4.32% |
| 2010-12-31 | $64.21K | -- |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola a… Read more